[{"id":"cf51fac2-f996-42c3-ad9d-9fbe49593e74","acronym":"KEYNOTE-E90","url":"https://clinicaltrials.gov/study/NCT05872867","created_at":"2023-05-24T18:06:24.421Z","updated_at":"2025-02-25T16:18:49.806Z","phase":"Phase 1","brief_title":"Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)","source_id_and_acronym":"NCT05872867 - KEYNOTE-E90","lead_sponsor":"Wellmarker Bio","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 underexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • WM-A1-3389"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/14/2024","start_date":" 03/14/2024","primary_txt":" Primary completion: 02/22/2026","primary_completion_date":" 02/22/2026","study_txt":" Completion: 02/22/2026","study_completion_date":" 02/22/2026","last_update_posted":"2024-03-11"}]